Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic

NicVAX(®), a nicotine vaccine (3’AmNic-rEPA), has been clinically evaluated to determine if higher antibody concentrations are associated with higher smoking abstinence rates and if doses and frequency of administration are associated with increased antibody response. This randomized, double-blinded...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Hatsukami, Dorothy K., Jorenby, Douglas E., Gonzales, David, Rigotti, Nancy A., Glover, Elbert D., Oncken, Cheryl A., Tashkin, Donald P., Reus, Victor I., Akhavain, Roxanne C., Fahim, Raafat E.F., Kessler, Paul D., Niknian, Minoo, Kalnik, Matthew W., Rennard, Stephen I.
Формат: Artigo
Язык:Inglês
Опубликовано: 2011
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4106715/
https://ncbi.nlm.nih.gov/pubmed/21270788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/clpt.2010.317
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы